Supportive care, cognition and quality of life in brain metastases

Affiliation auteurs!!!! Error affiliation !!!!
TitreSupportive care, cognition and quality of life in brain metastases
Type de publicationJournal Article
Year of Publication2015
AuteursLe Rhun E., Taillibert S., Blonski M., N. Delbez J, Delgadillo D., Taillia H., Auquier P., Belin C., Bonnetain F., Varin D., Tallet A., Taillandier L.
JournalCANCER RADIOTHERAPIE
Volume19
Pagination55-60
Date PublishedFEB
Type of ArticleArticle
ISSN1278-3218
Mots-clésbrain metastases, Cognition, Corticotherapy, epilepsy, Quality of life, Thromboembolic disease
Résumé

Brain metastases impact on the survival of the patients, but on their quality of life as well. The objective of the management of these patients is then double. Currently, due to medical advances, survivals tend to improve, especially for some tumor subtypes. During the course of the disease, different neurological signs and symptoms can be observed according to the location, the number and the volume of the metastase(s). Patients and caregivers are especially worried about the loss of autonomy and cognitive impairments. A permanent dialogue, during the course of the disease, is mandatory, in order to adapt the management to the objectives determined by the patients and the medical team. These objectives may vary according to the objective response rates of the disease to anticancer therapies, according to the impact of the disease and its management in daily living. Anticancer therapies and supportive care must be appreciated according to their impact on the survival, on the preservation of the functional independence and the quality of life of the patient, on their abilities to preserve the neurological status and delay the apparition of new neurological signs and symptoms, and their adverse events. Supportive care, cognition and quality of life should be regularly evaluated and adapted according to the objectives of the management of brain metastases patients. Different approaches are described in this paper. (C) 2015 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

DOI10.1016/j.canrad.2014.11.003